

XTL BIOPHARMACEUTICALS LTD

Form 424B3

October 04, 2012

October 1, 2012

Securities & exchange Commission  
450 Fifth Street, NW  
Washington, DC 20549

Attn.: Document Control

RE: American Depositary Shares  
evidenced by the American Depositary  
Receipts each representing Two (2) Ordinary  
Shares of XTL Biopharmaceuticals Ltd.  
(Form F-6 File No. 333-147677)

Ladies and Gentlemen:

Pursuant to Rule 424(b)(3) under the  
Securities Act of 1933, as amended, on  
behalf of The Bank of New York, as  
Depositary for securities against which  
American Depositary Receipts are to be  
issued, we attach a copy of the new  
prospectus (Prospectus) reflecting in number  
of ordinary shares represented by one  
American Depositary Share (the Ratio).

As required by Rule 424(e), the upper right  
hand corner of the Prospectus cover page has  
a reference to Rule 424(b)(3) and to the file  
number of the registration statement to which  
the Prospectus relates.

Pursuant to Section III B of the General  
Instructions to the Form F-6 Registration  
Statement, the Prospectus consists of the  
ADR certificate with revised ratio for XTL  
Biopharmaceuticals Ltd.

The Prospectus has been revised to reflect  
the new ratio and has been overstamped  
with:

Effective October 4, 2012 the Companys  
American Depositary Share (ADS) Ratio  
Changed from 1:2 (One ADS  
Representing Two deposited Shares to  
1:20 (One ADS Representing Twenty  
deposited Shares).

Please contact me with any questions or  
comments at 212 815-8223

Agness Moskovits  
The Bank of New York Mellon - ADR

Edgar Filing: XTL BIOPHARMACEUTICALS LTD - Form 424B3

Division

Encl.

CC: Paul Dudek, Esq. (Office of International  
Corporate Finance)

101 Barclay Street, New York NY 10286